Clinical results with the AB-180 left ventricular assist device.
BACKGROUND
This report reviews the initial clinical experience with the AB-180 ventricular assist device.


METHODS
Between Dec 1997 and July 2000, the AB-180 was implanted in 17 patients at five institutions. The mean age was 52 years (range 21 to 68 years) and 14 of 17 were male. The indications for implantation were postcardiotomy shock (12 of 17, 70%), decompensated cardiomyopathy (2 of 17, 12%), viral myocarditis (2 of 17, 12%), and acute myocardial infarction (1 of 17, 6%).


RESULTS
The mean duration of support was 8.5 days (range 1 to 28 days). In the group of 17 patients, 8 were weaned from the device and 2 underwent transplantation. Four of the weaned patients (4 of 8, 50%) and 1 of the transplant patients (1 of 2, 50%) survived. The overall weaning and survival rates were 58% (10 of 17) and 29% (5 of 17). There were no major device-related complications and no major device malfunctions.


CONCLUSIONS
The AB-180 provides reliable circulatory support for reversible forms of heart failure.
Magovern
J A
JA
Department of Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA. jmagover@wpahs.org
Sussman
M J
MJ
Goldstein
A H
AH
Szydlowski
G W
GW
Savage
E B
EB
Westaby
S
S
D000328:Adult; D000368:Aged; D004867:Equipment Design; D005260:Female; D006331:Heart Diseases / Q000601:surgery*; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome